Newron Completes Enrollment in Phase 3 Evenamide Trial for Treatment-Resistant Schizophrenia

(AWP Alliance News) - Newron Pharmaceuticals completed enrollment in its pivotal Phase 3 ENIGMA-TRS 1 trial of evenamide on Oct. 22, 2026, with 618 patients randomized. The trial is evaluating the experimental drug as an add-on to second-generation antipsychotics for treatment-resistant schizophrenia.

Enrollment spanned more than 80 study centers in 19 countries. Topline 12-week results are expected in the first quarter of 2027. The trial will remain double-blind and placebo-controlled through 52 weeks.

https://www.publicnow.com/view/7A0DCE4A32A7DFF24106BC248C8919ABB0D09AF8…

Disclaimer: This news brief was created using generative artificial intelligence. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief via EQS News on October 22, 2026, and is solely responsible for the information contained therein.